Democratizing Tumor Genomic Profiling With Tailored Content
To advance research for precision oncology, it is essential to identify molecular changes that underly tumorigenesis.
Now you can tailor tumor genomic profiling assays by customizing next-generation sequencing (NGS) cancer panels to fit your laboratory’s specific requirements, including the assessment of new and emerging biomarkers, the immuno-oncology biomarkers (tumor mutational burden (TMB) and microsatellite instability (MSI)), and homologous recombination deficiency (HRD).
Agilent SureDesign, a user-friendly panel design software powered by machine learning, offers fast and easy design of Agilent SureSelect Cancer Custom panels to enable detection of key classes of somatic alterations.
In this webinar, you will learn about:
- The range of available tumor genomic profiling assays (comprehensive, tumor-specific, customized) in the Agilent SureSelect Cancer product portfolio
- Designing customized cancer panels with SureDesign, by leveraging globally curated, cancer-specific genes and curating your own gene list
- Achieving high-quality results from samples such as formalin-fixed, paraffin-embedded (FFPE) tissues
- Improving lab efficiency by streamlining library preparation and target enrichment with automation, reducing hands-on time to as little as 15 minutes
- Integrated workflows incorporating NGS sample and library QC, compatibility across multiple sequencing platforms, and informatics options
Presenter: Danielle Fletcher (Field Applications Scientist, Agilent Technologies)
Danielle is a member of Agilent’s European custom design service. This team assists customers by creating custom NGS target enrichment panels as well as CGH and GE microarrays designs.
Presenter: Michael Ruvolo, Ph.D. (Director, R&D, Agilent Technologies)
Mike is the director of NGS content development at Agilent Technologies.
He and his team are responsible for assay development using SureSelect NGS target enrichment technology.
